Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

HEART DISEASE Clinical Trial

— ProQuad®  

Official title:

A Prospective, Multisite Study to Evaluate the Impact of Measles, Mumps, Rubella and Varicella ProQuad® Vaccination in Pediatric Patients 6-24 Months of Age Who Are Being Considered and/or Evaluated for Any Solid Organ Transplant

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02687763
• Other study ID #: Pro25854
• Status: Completed
• Phase: Early Phase 1
• Start date: December 2015
• Est. completion date: November 3, 2016

Study information

• Verified date: February 2019
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, multisite study to evaluate the Impact of Measles, Mumps, Rubella and Varicella ProQuad® vaccination in pediatric patients 6-24 months of age who are being considered and/or evaluated for any solid organ transplant (heart, liver or kidney)

Description:

Primary Aim:

To measure the antibody response to ProQuad® vaccination given earlier than the current recommended age in patients from the age of 6 months to 24 months who are being considered and/or evaluated for any solid organ transplant (heart, liver or kidney) within the next five years. These subjects would not reach the recommended ages to receive the vaccine before the transplant.

Hypothesis:

The Investigator proposes the hypothesis that the proposed study population will mount a clinically significant response to two (2) doses of the ProQuad® vaccine.

Primary Endpoint:

With respect to expected outcomes, the work proposed is expected to provide tools for optimizing the ProQuad® vaccination strategy in this population.

Secondary Aim:

To determine the safety of ProQuad® vaccination in children aged 6 months to 24 months who are being considered and/or evaluated for any solid organ transplant (heart, liver, kidney).

Hypothesis :

The Investigator proposes the hypothesis that the study population will have similar safety profiles compared to children who receive the vaccine at the recommended ages.

Secondary Endpoint:

The secondary outcome measure is represented by the children in the study having either no adverse effects or minimal adverse effects from the ProQuad® vaccine. Adverse effects will be monitored via Electronic Medical Records (EMR) for Emergency Department (ED), hospital or clinic visits, follow-up phone calls to the family/subjects, as well as the vaccination report card that the parents/legal guardians of the participants in the study will complete for their child for 7 days after he/she receives each dose of the vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: November 3, 2016
• Est. primary completion date: November 3, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 24 Months

Eligibility

Inclusion Criteria:

1. Parent and/or legal guardian willing and able to give informed consent.

2. Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:

• to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.

• to participate in the three (3) antibody titer blood draws.

Exclusion Criteria:

1. History of allergy to any vaccine component, bleeding disorder, exposure to measles, mumps, rubella, varicella, or zoster in the 30 days prior to vaccination.

2. Receipt of any blood product or immunoglobulin received in the previous 180 days prior to vaccination.

3. Previously received any measles, mumps, rubella and/or varicella vaccine either alone or in combination prior to vaccination.

4. Any condition which causes the investigator to determine that the subject is not appropriate to enroll.

Related Conditions & MeSH terms

• HEART DISEASE
• Heart Diseases
• Hepatic Insufficiency
• Liver Failure
• Liver Failure, Acute
• Renal Insufficiency
• RENAL INSUFFICIENCY, CHRONIC

Intervention

Biological:
• ProQuad
2) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing: to receive two doses of ProQuad® at least 30 days but no more than 365 days apart. to participate in the three (3) antibody titer blood draws.

Locations

Country	Name	City	State
United States	Medical University of South Carolina, Pediatric Nephrology	Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Varicella IgG Antibody Titer = 1.1 IU/ml	Percentage of Participants with Varicella IgG Antibody Titer = 1.1 IU/ml: at least 30 days to less than 365 days post vaccination.	"at least 30 days to less than 365 days post vaccination"
Primary	Measles IgG Antibody Titer = 30AU/ml	Percentage of Participants with post vaccination Measles IgG Antibody Titer = 30AU/ml: at least 30 days to less than 365 days post vaccination.	"at least 30 days to less than 365 days post vaccination"
Primary	Mumps IgG Antibody Titer = 11AU/ml	Percentage of Participants tested for Mumps IgG Antibody Titer = 11AU/ml: at least 30 days to less than 365 days post vaccination.	"at least 30 days to less than 365 days post vaccination"
Primary	Rubella IgG Antibody Titer = 15 IU/mL	Percentage of Participants tested for Rubella IgG Antibody Titer = 15 IU/mL: at least 30 days to less than 365 days post vaccination.	"at least 30 days to less than 365 days post vaccination"
Secondary	Geometric Mean Titer (GMT) of Varicella Antibody	Geometric Mean Titer (GMT) of Varicella Antibody participating subjects at three different points in time. Antibody titers will be reported as geometric mean concentrations (GMCs) with 95% confidence intervals (CIs). Responses to historical controls will be compared by Student paired or unpaired t test and Fisher exact test. P < .05 will be considered statistically significant.	"at least 30 days to less than 365 days post vaccination"
Secondary	Geometric Mean Titer (GMT) of Measles Antibody	Geometric Mean Titer (GMT) of Measles Antibody participating subjects at three different points in time. Antibody titers will be reported as geometric mean concentrations (GMCs) with 95% confidence intervals (CIs). Responses to historical controls will be compared by Student paired or unpaired t test and Fisher exact test. P < .05 will be considered statistically significant.	"at least 30 days to less than 365 days post vaccination"
Secondary	Geometric Mean Titer (GMT) of Mumps Antibody	Geometric Mean Titer (GMT) of Mumps Antibody participating subjects at three different points in time. Antibody titers will be reported as geometric mean concentrations (GMCs) with 95% confidence intervals (CIs). Responses to historical controls will be compared by Student paired or unpaired t test and Fisher exact test. P < .05 will be considered statistically significant.	"at least 30 days to less than 365 days post vaccination"
Secondary	Geometric Mean Titer (GMT) of Rubella Antibody	Geometric Mean Titer (GMT) of Rubella Antibody participating subjects at three different points in time. Antibody titers will be reported as geometric mean concentrations (GMCs) with 95% confidence intervals (CIs). Responses to historical controls will be compared by Student paired or unpaired t test and Fisher exact test. P < .05 will be considered statistically significant.	"at least 30 days to less than 365 days post vaccination"